Takeda Pharmaceuticals U.S.A. Inc.
1 Takeda Pkwy
About Takeda Pharmaceutical
Millennium Pharmaceuticals was established in 1993 as a genomics company, applying world-class molecular biology and genomic technologies to the discovery and development of new therapies in a broad spectrum of diseases. Over time we evolved into a fully integrated biopharmaceutical company.
In May 2008, Millennium was acquired by Takeda Pharmaceutical Company Limited in Japan and became known as Millennium: The Takeda Oncology Company (Millennium), a wholly-owned subsidiary of Takeda that served as the organization’s global center of excellence in oncology.
The combination of oncology resources resulted in a robust pipeline that addresses a broad range of cancers. Our focus is to improve the treatment of cancer, which gives us an important oncology mission to deliver extraordinary medicines to patients with cancer worldwide through our science, innovation and passion, toward an ultimate goal and aspiration to cure cancer.
In May 2013, the decision was made to fully integrate Millennium into the global Takeda R&D engine to maximize the resources available from the broader Takeda organization and to realize greater operational efficiencies. The R&D and G&A functions in Boston became known publically as Takeda Pharmaceuticals International Co. The oncology Commercial, Business Development and Patient Advocacy divisions continue to operate as Millennium: The Takeda Oncology Company.
At Takeda and Millennium, we want to exceed expectations in terms of progress against cancer, distinguishing ourselves within the research-based biopharmaceutical community. We’re prepared to deliver on this goal by focusing on novel or best-in-class drug candidates, and cultivating the brightest talent. This puts Takeda on an exciting path toward global oncology leadership.
We help drive and accelerate the progress that continually is being made against cancer; these advances, sometimes big breakthroughs and sometimes incremental, make a real difference in the lives of patients. We won’t be satisfied until cures are found and the threat is removed. People who battle cancer deserve no less.
Our goal also is to provide patients and people close to them with easily understandable information about the diseases our products treat, as well as other relevant information and service resources. We also provide information about our investigational drugs that are approaching or in development, our clinical trials, and what patients, caregivers and healthcare providers need to know about our assistance and access programs for any drug we currently market. We work toward our goals with the same urgency for patients that we would for our families. We strive to earn the respect and admiration of the global oncology community by delivering significant progress against cancer while living our core values.
The people and culture at Takeda and Millennium make all the difference.
Our work is more than a job. We are entrepreneurial about both our work and achieving progress. We focus on what’s important and timely decision-making.
As a site based in New England, we enjoy our local community and contribute in many ways to local business, social and environmental causes. We offer a broad range of opportunities for campus-based employees to participate. We also involve ourselves on a corporate level in matters of social responsibility.
June 12, 1781
Founder: Chobei Takeda
CEO: Christophe Weber
CMO (Medical) and CSO (Scientific): Andrew Plump
CFO: James Kehoe
Please click here for Takeda job opportunities.
Tweets by Takeda
830 articles with Takeda Pharmaceutical
Takeda Pharmaceutical has come back to the bargaining table with a juicier bid for Shire. Yesterday, Takeda’s $60 billion-plus bid for Shire took an odd turn late yesterday when Dublin, Ireland-based Allergan was reported to be in talks with Shire as well. However, by the end of the day, Allergan...
UPDATED: Shire Rejects Takeda’s $60 Billion Acquisition Bid and Allergan Reportedly In Talks with...
4/19/2018Takeda Pharmaceutical has made an official bid to acquire London’s Shire for about $60 billion. And in breaking news, Shire rejected the bid, saying it undervalued the company.
Sanofi has agreed to sell its generics division, Zentiva, to Advent International. The deal is expected to wrap by the end of this year.
Shares of Ironwood Pharma have settled a bit after the company announced Monday that activist investor Alex Denner of Sarissa Capital was vying for a seat on the company board of directors.
Investors in Ionis Pharmaceuticals are happy this morning after the company announced it struck another licensing deal with AstraZeneca that has the potential to yield up to $330 million.
Shares of Shire Plc spiked overnight after increased rumors that Japanese pharma giant Takeda could be closer to making a deal to acquire the rare disease company.
The $40 billion market for nonalcoholic steatohepatitis (NASH) is becoming a little more crowded. Less than one year after launching Terns Pharmaceuticals acquired exclusive licensing rights to three small molecule therapeutic NASH candidates from Eli Lilly.
Yesterday’s news that Takeda Pharmaceuticals was considering acquiring Shire is raising the possibility of a bidding war. But it’s also having decidedly different effects on the two companies’ stock prices.
Shire stock prices jumped up to 26 percent on rumors that Takeda Pharmaceuticals was considering a buyout.
ImmunoGen, released positive efficacy and tolerability data from its FORWARD II trial of its mirvetuximab soravtansine in combination with Merck’s Keytruda in platinum-resistant epithelial ovarian cancer (EOC). Shares jumped almost 12 percent in premarket trading.
Healthcare companies are now looking at pharma executives for leadership roles as the landscape of healthcare is dramatically changing.
Rheos Medicines, backed by Third Rock Ventures, launched with a $60 million Series A financing. The company will focus on immunometabolism to treat disease.
Takeda Announces Publication of Final Data from ICLUSIG® (ponatinib) Pivotal Phase 2 PACE Trial in Blood
Final five-year results show ICLUSIG continued to provide clinically meaningful responses, with depth and lasting duration, irrespective of dose reductions, in heavily pre-treated chronic-phase chronic myeloid leukemia patients
Seattle Genetics announced today that the FDA has granted approval for its Adcetris drug to treat Hodgkins Lymphoma.
Denali Therapeutics, located in South San Francisco, California, had a lot of news to share today.
AbbVie and Neurocrine Biosciences announced that its Phase III ELARIS UF-II trial of elagolix for uterine fibroids met its primary endpoint.
Shares of weight-loss drugmaker Orexigen Therapeutics are in free-fall this morning after the company announced it filed for bankruptcy.
Finch Therapeutics closed on an oversubscribed Series B financing worth $36 million.
Mindstrong Health and Takeda Partner to Explore Development of Digital Biomarkers for Mental Health Conditions
Deal combines Mindstrong's digital phenotyping platform with Takeda's development capabilities
Beacon Discovery announces multi-year GPCR drug discovery collaboration with Takeda focused on gastrointestinal disorders
Beacon Discovery today announced the formation of a multi-year drug discovery collaboration with Takeda Pharmaceutical Company Limited focused on a number of G-protein coupled receptors (GPCRs) that play an important role in the pathology of gastrointestinal disorders.